Expertise in
14
conditions

Dr. Amanda Parkes

Hematology
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 
Clinical Trials:Currently Recruiting for 1 Trial
Expertise in
14
conditions
UT MD Anderson Cancer Center
210 Ashville Ave # 408, 
Cary, NC 

Overview

Amanda Parkes is a Hematologist practicing medicine in Cary, North Carolina.

Dr. Parkes is highly rated in 14 conditions, according to our data. Her clinical expertise encompasses Liposarcoma, Adult Soft Tissue Sarcoma, Bone Tumor, and Undifferentiated Pleomorphic Sarcoma.

She is actively involved in clinical research, co-authoring 29 peer reviewed articles and participating in 5 clinical trials.

Specialties

Hematology

Licenses

Internal Medicine in WI

Languages Spoken

English

Gender

Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO

Locations

UT MD Anderson Cancer Center
210 Ashville Ave # 408, Cary, NC 27518

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
A Randomized, Phase II Trial of Circulating Tumor DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)
Enrollment Status: Recruiting
Publish Date: October 16, 2025
Intervention Type: Drug
Study Drugs: Palbociclib, Fulvestrant, Adjuvant Therapy
Study Phase: Phase 2
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
A Phase II, Single Arm, Non-randomized Study of Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer
Enrollment Status: Active_not_recruiting
Publish Date: January 02, 2026
Intervention Type: Drug
Study Drugs: Alpelisib, Fulvestrant, Aromatase Inhibitor
Study Phase: Phase 2
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
A Randomized, Double-Blind, Phase III Trial of Taxane/Trastuzumab/Pertuzumab With Atezolizumab or Placebo in First-Line HER2-Positive Metastatic Breast Cancer
Enrollment Status: Completed
Publish Date: December 30, 2025
Intervention Type: Other, Procedure, Biological, Drug
Study Drugs: Atezolizumab, Paclitaxel, Pertuzumab, Trastuzumab
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Nirogacestat Versus Placebo in Adult Patients With Progressing Desmoid Tumors/Aggressive Fibromatosis (DT/AF)
Enrollment Status: Completed
Publish Date: January 31, 2025
Intervention Type: Drug
Study Drug: Nirogacestat Oral Tablet
Study Phase: Phase 3
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
A randoMized phAse II trIal of fulvestraNt wiTh or Without Ribociclib After Progression on AntI-estrogeN Therapy Plus Cyclin-dependent Kinase 4/6 Inhibition in Patients With Unresectable or Metastatic Hormone Receptor +, HER2 - Breast Cancer (MAINTAIN Trial)
Enrollment Status: Completed
Publish Date: December 06, 2024
Intervention Type: Drug
Study Drugs: LEE-011, Fulvestrant
Study Phase: Phase 2
View 4 Less Clinical Trials

29 Total Publications

A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
A Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Journal: Clinical breast cancer
Published: August 14, 2024
Similar Doctors
Expertise in
40
conditions
Dr. Tapan Kadia
Hematology
Expertise in
40
conditions
Dr. Tapan Kadia
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tapan Kadia is a Hematologist practicing medicine in Cary, North Carolina. Dr. Kadia is highly rated in 40 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Leukemia, Prolymphocytic Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology
Expertise in
33
conditions
Dr. Prithviraj Bose
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Prithviraj Bose is a Hematologist practicing medicine in Cary, North Carolina. Dr. Bose is highly rated in 33 conditions, according to our data. His clinical expertise encompasses Myelofibrosis, Essential Thrombocythemia, Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
30
conditions
Dr. Richard Champlin
Hematology
Expertise in
30
conditions
Dr. Richard Champlin
Hematology

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
 (1050.4 miles away)
713-792-6161
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Richard Champlin is a Hematologist practicing medicine in Cary, North Carolina. Dr. Champlin is highly rated in 30 conditions, according to our data. His clinical expertise encompasses Acute Myeloid Leukemia (AML), Graft Versus Host Disease (GvHD), Leukemia, Bone Marrow Transplant, and Bone Marrow Aspiration.

Frequently Asked Questions about Dr. Amanda Parkes

How do I make an appointment with Dr. Amanda Parkes?

You can book an appointment with Dr. Amanda Parkes by calling their office at 713-792-6161. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Amanda Parkes a top-rated expert for Liposarcoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Amanda Parkes is classified as an Advanced expert for Liposarcoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Amanda Parkes specialize in?

While Dr. Amanda Parkes is a Hematology, they have specific expertise in Liposarcoma, Adult Soft Tissue Sarcoma, and Bone Tumor. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Amanda Parkes participate in research or clinical trials?

Yes. Dr. Amanda Parkes has published 29 articles and abstracts on conditions like Liposarcoma. You can view a list of Dr. Amanda Parkes's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Amanda Parkes accept my insurance?

Dr. Amanda Parkes accepts most major insurance plans, including Humana. We recommend calling the office directly at 713-792-6161 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Parkes's expertise for a condition
ConditionClose
      View All 14 Advanced Conditions
      View All 16 Experienced Conditions
      Want to save this doctor for later?
      Sign Up
      Is this your doctor?
      Find A Second Opinion
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile